Related references
Note: Only part of the references are listed.Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database
Joachim Alexandre et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
G. Curigliano et al.
ANNALS OF ONCOLOGY (2020)
Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event
Jennifer Cautela et al.
CANADIAN JOURNAL OF CARDIOLOGY (2020)
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry
Jose Lopez-Sendon et al.
EUROPEAN HEART JOURNAL (2020)
Cardiovascular megnetic resonance in immune checkpoint Inhibitor-associated myocarditis
Lili Zhang et al.
EUROPEAN HEART JOURNAL (2020)
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
Charles Dolladille et al.
JAMA ONCOLOGY (2020)
Cardio-Oncology Services: rationale, organization, and implementation A report from the ESC Cardio-Oncology council
Patrizio Lancellotti et al.
EUROPEAN HEART JOURNAL (2019)
Cardiovascular toxicities associated with immune checkpoint inhibitors
Jiun-Ruey Hu et al.
CARDIOVASCULAR RESEARCH (2019)
Cardioprotection in cancer therapy: novel insights with anthracyclines
Inbar Raber et al.
CARDIOVASCULAR RESEARCH (2019)
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Donna K. Arnett et al.
CIRCULATION (2019)
Cardio-Oncology: Vascular and Metabolic Perspectives A Scientific Statement From the American Heart Association
Umberto Campia et al.
CIRCULATION (2019)
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension
S. Bringhen et al.
JOURNAL OF INTERNAL MEDICINE (2019)
Anticoagulation Strategies in Patients With Cancer JACC Review Topic of the Week
Ramya C. Mosarla et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH
Aurelien Delluc et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Myocarditis in the Setting of Cancer Therapeutics Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology
Marc P. Bonaca et al.
CIRCULATION (2019)
Takotsubo syndrome in patients with cancer treated with immune checkpoint inhibitors: a new adverse cardiac complication
Stephane Ederhy et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
Khashayar Esfahani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis
Joe-Elie Salem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma
Robert F. Cornell et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Real-Life Insight Into Ibrutinib Cardiovascular Events Defining the Loose Ends
Jutta Bergler-Klein
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Cardiovascular Toxicities Associated With Ibrutinib
Joe-Elie Salem et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies
Anand P. Singh et al.
CARDIOVASCULAR RESEARCH (2019)
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice
John G. Gribben et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial
Daniela Cardinale et al.
EUROPEAN JOURNAL OF CANCER (2018)
Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention
Saro H. Armenian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Risk of Arterial Thrombosis in Cancer Patients Which Role for Cancer Therapies Vascular Toxicities?
Corinne Frere et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S. Mahmood et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms
Joachim Alexandre et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes The SUCCOUR Trial
Tomoko Negishi et al.
JACC-CARDIOVASCULAR IMAGING (2018)
2018 ESC/ESH Guidelines for the management of arterial hypertension
Bryan Williams et al.
EUROPEAN HEART JOURNAL (2018)
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
Sara Bringhen et al.
HAEMATOLOGICA (2018)
Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors
Stephen J. H. Dobbin et al.
HEART (2018)
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
Joe-Elie Salem et al.
LANCET ONCOLOGY (2018)
Cardiovascular Complications of Cancer Therapy Best Practices in Diagnosis, Prevention, and Management: Part 2
Hui-Ming Chang et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Risk of Arterial Thromboembolism in Patients With Cancer
Babak B. Navi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity
Marion Escudier et al.
CIRCULATION (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis
Husam Abdel-Qadir et al.
CANCER TREATMENT REVIEWS (2017)
Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy A Cross-sectional Study
Daniel A. Mulrooney et al.
ANNALS OF INTERNAL MEDICINE (2016)
Vascular Complications of Cancer Chemotherapy
Alan C. Cameron et al.
CANADIAN JOURNAL OF CARDIOLOGY (2016)
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy
Sean A. Virani et al.
CANADIAN JOURNAL OF CARDIOLOGY (2016)
Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling
L. de Zwart et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
QT interval variability in body surface ECG: measurement, physiological basis, and clinical value: position statement and consensus guidance endorsed by the European Heart Rhythm Association jointly with the ESC Working Group on Cardiac Cellular Electrophysiology
Mathias Baumert et al.
EUROPACE (2016)
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
Jose Luis Zamorano et al.
EUROPEAN HEART JOURNAL (2016)
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo F. Piepoli et al.
EUROPEAN HEART JOURNAL (2016)
Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives
Jennifer Cautela et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cardiovascular Toxic Effects of Targeted Cancer Therapies
Javid J. Moslehi
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Javid J. Moslehi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies Focus on Kinase Inhibitors
Weijuan Li et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Cardiovascular Health of Patients With Cancer and Cancer Survivors A Roadmap to the Next Level
Ana Barac et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Cancer survival: global surveillance will stimulate health policy and improve equity
Michel P. Coleman
LANCET (2014)
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
Juan Carlos Plana et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2014)
Modifiable Risk Factors and Major Cardiac Events Among Adult Survivors of Childhood Cancer
Gregory T. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
T. D. Kim et al.
LEUKEMIA (2013)
Late Cardiac Effects of Cancer Treatment
Daniel J. Lenihan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML
Karl J. Aichberger et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Impact of Comorbidity on Chemotherapy Use and Outcomes in Solid Tumors: A Systematic Review
Linda Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Imaging, and Cardiac Magnetic Resonance Imaging in Predicting Early Left Ventricular Dysfunction in Patients With Human Epidermal Growth Factor Receptor II-Positive Breast Cancer Treated With Adjuvant Trastuzumab Therapy
Nazanin Fallah-Rad et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Prevention of Torsade de Pointes in Hospital Settings A Scientific Statement From the American Heart Association and the American College of Cardiology Foundation Endorsed by the American Association of Critical-Care Nurses and the International Society for Computerized Electrocardiology
Barbara J. Drew et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy
Mark Belham et al.
EUROPEAN JOURNAL OF HEART FAILURE (2007)
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition
Daniela Cardinale et al.
CIRCULATION (2006)
Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy
D Cardinale et al.
CIRCULATION (2004)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
D Cardinale et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2000)
Share Paper
